ExpreS2ion will present its technology platform and pipeline at several key events in September and October 2020
ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate at several key events in September and October, including Aktiespararna’s Aktiedagen, September 15 in Lund, Sweden, World Vaccine Congress Washington Virtual, September 28–October 1, and World Vaccine Congress Europe Digital Event, October 19–21.
During these and additional scientific and business partnering meetings, ExpreS2ion will present the advantages of the ExpreS2 protein production and capsid virus-like particle (cVLP) technology platforms for vaccine discovery, preclinical development and good manufacturing practice (GMP) production for clinical studies, with a special focus on its COVID-19 vaccine project in collaboration with its joint venture AdaptVac.
CEO Bent Frandsen comments
“Our ExpreS2 platform is a leading tool for rapid development and GMP production of advanced and hard-to-express vaccines, as shown by its use in several high-profile malaria projects and the PREVENT-nCoV COVID-19 vaccine development program. With an ambitious clinical program for the COVID-19 vaccine planned for 2021, and the recent announcement that we intend to in-license the promising AV001 breast cancer vaccine candidate from our joint venture AdaptVac, we are now executing on our plan to take ExpreS2ion to the next level with an in-house pipeline of vaccine development projects. At these events, we hope to meet potential collaboration partners as well as presenting our company to shareholders and other stakeholders. I am excited to lead ExpreS2ion and our continued work to create world-class treatments for some of the most important medical challenges of our time.”
ExpreS2ion will participate in the following event activities in September and October, 2020:
Aktiespararna’s Aktiedagen, September 15, Lund, Sweden
See the company presentation by our CEO, Bent U. Frandsen, at this investor event, which is digital and broadcasted live. Make a participant reservation at Aktiespararna's website.
World Vaccine Congress Washington Virtual, September 28–October 1
To learn more about ExpreS2 and the unique VLP technology, see Dr. Max Soegaard, VP R&D, present our proof-of-concept in animals-stage COVID-19 vaccine project. Pre-arrange meetings via email on info@expreS2ionbio.com. More information at WVC’s website.
Webinar on Denmark’s response to COVID-19, September 29, Japan
ExpreS2ion and its joint venture AdaptVac’s involvement in the PREVENT-nCoV COVID-19 vaccine program is presented by CEO Bent U. Frandsen at this webinar aimed at a Japanese audience. The event highlights Denmark’s efforts in response to the COVID-19 pandemic. It is co-hosted by the Danish public-private partnership organization Healthcare Denmark and the Royal Danish Embassy, Tokyo. Registration and more information about the event via the following links:
World Vaccine Congress Europe Digital Event, October 19–21
To learn more about ExpreS2 and the unique VLP technology, see Dr. Max Soegaard, VP R&D, present our proof-of-concept in animals-stage COVID-19 vaccine project. Pre-arrange meetings via email on info@expreS2ionbio.com. More information at WVC Europe’s website.
Life Science Investor Conference by Økonomisk Ugebrev, October 21, Denmark
See the company presentation by our CEO, Bent U. Frandsen, at this investor event. The presentation will be held in Danish. More information at the webpage of the event.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.